Investor Hub

Lakefront Biotherapeutics is a biotechnology company building a differentiated clinical-stage pipeline in immunology and inflammation, anchored by lead asset gamgertamig, a potential first-in-class BCMAxCD3 T-cell engager for autoimmune diseases.

With deep deal-making expertise, operational flexibility, and a strong capital position, Lakefront identifies, acquires, and advances high-quality assets with clear potential to deliver meaningful patient impact and long-term shareholder value.